These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

163 related articles for article (PubMed ID: 21714794)

  • 1. Development of a refractory gastro-oesophageal reflux score using an administrative claims database.
    Gerson LB; Bonafede M; Princic N; Gregory C; Farr A; Balu S
    Aliment Pharmacol Ther; 2011 Sep; 34(5):555-67. PubMed ID: 21714794
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Healthcare costs of GERD and acid-related conditions in pediatric patients, with comparison between histamine-2 receptor antagonists and proton pump inhibitors.
    Kothari S; Nelson SP; Wu EQ; Beaulieu N; McHale JM; Dabbous OH
    Curr Med Res Opin; 2009 Nov; 25(11):2703-9. PubMed ID: 19775195
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Evaluation of treatment for gastro-oesophageal reflux disease with a proton pump inhibitor, and relationship between gastro-oesophageal reflux disease and Helicobacter pylori infection in Japan.
    Muramatsu A; Azuma T; Okajima T; Ohtani M; Dojo M; Yamazaki Y; Kuriyama M
    Aliment Pharmacol Ther; 2004 Jul; 20 Suppl 1():102-6. PubMed ID: 15298614
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Clinical trial: persistent gastro-oesophageal reflux symptoms despite standard therapy with proton pump inhibitors - a follow-up study of intraluminal-impedance guided therapy.
    Becker V; Bajbouj M; Waller K; Schmid RM; Meining A
    Aliment Pharmacol Ther; 2007 Nov; 26(10):1355-60. PubMed ID: 17900268
    [TBL] [Abstract][Full Text] [Related]  

  • 5. The impact of proton pump inhibitor compliance on health-care resource utilization and costs in patients with gastroesophageal reflux disease.
    Gosselin A; Luo R; Lohoues H; Toy E; Lewis B; Crawley J; Duh MS
    Value Health; 2009; 12(1):34-9. PubMed ID: 19895371
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Endoluminal gastroplication for the treatment of gastroesophageal reflux disease: a 2-year prospective pilot study from Taiwan.
    Liao CC; Lee CL; Lin BR; Bai CH; Hsieh YH; Wu CH; Gostout CJ
    J Gastroenterol Hepatol; 2008 Mar; 23(3):398-405. PubMed ID: 18318824
    [TBL] [Abstract][Full Text] [Related]  

  • 7. 24-hour ambulatory pH-metry in patients with refractory heartburn: a prospective study.
    Talaie R; Forootan M; Donboli K; Dadashzadeh N; Sadeghi A; Poorsaadat S; Moghimi B; Mohammad Alizadeh AH; Zali MR
    J Gastrointestin Liver Dis; 2009 Mar; 18(1):11-5. PubMed ID: 19337627
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Predictors of response to short-term proton pump inhibitor treatment in laryngopharyngeal reflux patients.
    Siupsinskiene N; Adamonis K; Toohill RJ; Sereika R
    J Laryngol Otol; 2008 Nov; 122(11):1206-12. PubMed ID: 18331659
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Increasing body weight enhances prevalence and proximal extent of reflux in GERD patients 'on' and 'off' PPI therapy.
    Blondeau K; Boecxstaens V; Van Oudenhove L; Farré R; Boeckxstaens G; Tack J
    Neurogastroenterol Motil; 2011 Aug; 23(8):724-e327. PubMed ID: 21535319
    [TBL] [Abstract][Full Text] [Related]  

  • 10. The use of acid-decreasing medication in veteran patients with gastro-oesophageal reflux disorder with and without Barrett's oesophagus.
    El-Serag HB; Wieman M; Richardson P
    Aliment Pharmacol Ther; 2008 Jun; 27(12):1293-9. PubMed ID: 18363892
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Ten-year outcome of laparoscopic and conventional nissen fundoplication: randomized clinical trial.
    Broeders JA; Rijnhart-de Jong HG; Draaisma WA; Bredenoord AJ; Smout AJ; Gooszen HG
    Ann Surg; 2009 Nov; 250(5):698-706. PubMed ID: 19801931
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Randomised clinical trial: sustained response to PPI treatment of symptoms resembling functional dyspepsia and irritable bowel syndrome in patients suffering from an overlap with erosive gastro-oesophageal reflux disease.
    Mönnikes H; Schwan T; van Rensburg C; Straszak A; Theek C; Sander P; Lühmann R
    Aliment Pharmacol Ther; 2012 Jun; 35(11):1279-89. PubMed ID: 22486552
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Gastroesophageal reflux disease in primary care: using changes in proton pump inhibitor therapy as an indicator of partial response.
    Ruigómez A; Johansson S; Wernersson B; Fernández Cantero O; García Rodríguez LA
    Scand J Gastroenterol; 2012 Jul; 47(7):751-61. PubMed ID: 22519917
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Prevalence of gastroesophageal reflux disease in Korea and associated health-care utilization: a national population-based study.
    Kim KM; Cho YK; Bae SJ; Kim DS; Shim KN; Kim JH; Jung SW; Kim N
    J Gastroenterol Hepatol; 2012 Apr; 27(4):741-5. PubMed ID: 21916988
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Frequency scale for symptoms of gastroesophageal reflux disease predicts the need for addition of prokinetics to proton pump inhibitor therapy.
    Miyamoto M; Haruma K; Takeuchi K; Kuwabara M
    J Gastroenterol Hepatol; 2008 May; 23(5):746-51. PubMed ID: 18028348
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Cost-effectiveness model of endoscopic biopsy for eosinophilic esophagitis in patients with refractory GERD.
    Miller SM; Goldstein JL; Gerson LB
    Am J Gastroenterol; 2011 Aug; 106(8):1439-45. PubMed ID: 21448144
    [TBL] [Abstract][Full Text] [Related]  

  • 17. [Retrospective analysis of coexistence of acidic gastroesophageal reflux in children with atopic bronchial asthma].
    Jedynak-Wasowicz U; Przybyszewska K; Szczerbiński T; Cichocka-Jarosz E; Groblicka M; Lis G; Fyderek K
    Przegl Lek; 2007; 64 Suppl 3():115-7. PubMed ID: 18431932
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Natural history of gastro-oesophageal reflux disease without oesophagitis (NERD)--a reappraisal 10 years on.
    Pace F; Bollani S; Molteni P; Bianchi Porro G
    Dig Liver Dis; 2004 Feb; 36(2):111-5. PubMed ID: 15002817
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Otolaryngologic manifestations of gastro-oesophageal reflux disease in Lagos.
    Somefun OA; Wanda CB; Adesanya AA; Thomas MO; Esan OO
    Niger Postgrad Med J; 2006 Sep; 13(3):225-9. PubMed ID: 17066111
    [TBL] [Abstract][Full Text] [Related]  

  • 20. The extent and determinants of prescribing and adherence with acid-reducing medications: a national claims database study.
    El-Serag HB; Fitzgerald S; Richardson P
    Am J Gastroenterol; 2009 Sep; 104(9):2161-7. PubMed ID: 19568229
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.